Momelotinib User Reviews & Ratings
Brand names: Ojjaara
Momelotinib has an average rating of 7.0 out of 10 from a total of 2 reviews on drugclasses.com. 50% of reviewers reported a positive experience, while 0% reported a negative experience.
Condition | Avg. Rating | Reviews | Compare |
---|---|---|---|
Myelofibrosis | 2 reviews for Myelofibrosis | 4 medications | |
Add your review |
- Jane
- Taken for 6 months to 1 year
- July 15, 2024
Ojjaara (momelotinib) for Myelofibrosis "Gait affected, frequent urination, aversion to some foods, depression"
Reviews may be edited to correct grammar/spelling or to remove inappropriate language and content. Reviews that appear to be created by parties with a vested interest are not published. This information is not intended to endorse any particular medication. While these reviews may be helpful, they are not a substitute for the expertise, knowledge, and judgement of healthcare professionals.
More about momelotinib
- Check interactions
- Compare alternatives
- Reviews (2)
- Side effects
- Dosage information
- During pregnancy
- Drug class: multikinase inhibitors
- Breastfeeding
- En español
Ojjaara (momelotinib) for Myelofibrosis "After 2 months of taking Ojjaara, I do have some loss of taste and smell. The first few weeks my stool was dark and tarry, but now more normal, but not all normal. I also have hundreds of tiny red bumps on my skin. I also see more skin rashes but cortisone cream does help. I have a mild cough that is daily, but that was going on even 10 months before Ojjaara. My spleen is still enlarged, but it has stopped growing. Before Ojjaara, my spleen caused pain when I took deep breaths, but not now. Yay! And that's a huge win. My blood count numbers are stable, however, my kidney function has dropped in the last 2 months, which makes me think it is from Ojjaara, but could be another myelofibrosis symptom."